Table 2.
Summary of CLOZUK3 variables used in mediation analysis.
| Male (N = 577) | Female (N = 234) | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Mean | SD | Min | Max | Mean | SD | Min | Max |
| [Clozapine] (mg/L) | 0.467 | 0.256 | 0.052 | 1.799 | 0.556 | 0.322 | 0.053 | 1.84 |
| [Norclozapine] (mg/L) | 0.259 | 0.145 | 0.052 | 1.234 | 0.313 | 0.186 | 0.059 | 1.03 |
| Daily dose (mg) | 360.637 | 136.473 | 100 | 900 | 324.797 | 134.547 | 100 | 900 |
| TDS (hours) | 13.479 | 2.305 | 6.5 | 24 | 13.618 | 2.062 | 10 | 23.5 |
| ANC (×109 cells/L) | 4.166 | 1.286 | 2.01 | 7.41 | 4.292 | 1.258 | 2.02 | 7.24 |
| Age | 39.099 | 11.863 | 18 | 68 | 42.406 | 12.804 | 19 | 84 |
Summary of CLOZUK3 variables used in mediation analysis. Descriptive statistics are presented for a ‘cross-sectional’ version of CLOZUK3 where only the entry associated with the lowest value of ANC per person is retained.
TDS Time between Dose and Sample, ANC Absolute Neutrophil Count, [Clozapine] Clozapine plasma concentration, [Norclozapine] Norclozapine plasma concentration.